Resolution of Serious Vaso-occlusive Pain Crises: Results From The Ongoing Phase 1/2 HGB-206 Group C Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

被引：0

作者：

Mapara, Markus ^{[1
]}

Walters, Mark ^{[2
]}

Thompson, Alexis ^{[3
,4
]}

Kwiatkowski, Janet ^{[5
,6
]}

Krishnamurti, Lakshmanan ^{[7
]}

Aygun, Banu ^{[8
]}

Kasow, Kimberly ^{[9
]}

Rifkin-Zenenberg, Stacey ^{[10
]}

Schmidt, Manfred ^{[11
]}

Nnamani, Mauris ^{[12
]}

VanNest, Sara ^{[12
]}

Pierciey, Francis, Jr. ^{[12
]}

Miller, Alex ^{[12
]}

Chen, Ren ^{[12
]}

Kim, Dennis ^{[12
]}

Goyal, Sunita ^{[12
]}

Kanter, Julie ^{[13
]}

Tisdale, John ^{[14
]}

机构：

[1] Columbia Univ, Med Ctr, New York, NY USA

[2] UCSF Benioff Childrens Hosp Oakland, Oakland, CA USA

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA

[5] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[6] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[7] Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA

[8] Cohen Childrens Med Ctr, Queens, NY USA

[9] Univ N Carolina, Chapel Hill, NC 27515 USA

[10] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[11] GeneWerk GmbH, Heidelberg, Germany

[12] Bluebird Bio Inc, Cambridge, MA USA

[13] Univ Alabama Birmingham, Birmingham, AL USA

[14] NIH, Bldg 10, Bethesda, MD 20892 USA

来源：

BONE MARROW TRANSPLANTATION | 2021年 / 56卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O056

引用

页码：66 / 68

页数：3

共 44 条

[41] Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning [J].

Grimley, Michael ;

Asnani, Monika ;

Shrestha, Archana ;

Felker, Sydney ;

Lutzko, Carolyn ;

Arumugam, Paritha I. ;

Witting, Scott ;

Knight-Madden, Jennifer ;

Niss, Omar ;

Quinn, Charles T. ;

Lo, Chris ;

Little, Courtney R. ;

Dong, Alisa ;

Malik, Punam .

BLOOD, 2021, 138

[42] Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral βA-T87Q Globin Vector (LentiGlobin BB305 Drug Product) [J].

Thompson, Alexis A. ;

Rasko, John E. ;

Hongeng, Suradej ;

Kwiatkowski, Janet L. ;

Schiller, Gary ;

von Kalle, Christof ;

Cavazzana, Marina ;

Leboulch, Philippe ;

Petrusich, Alexandria ;

Soni, Sandeep ;

Walters, Mark C. .

BLOOD, 2014, 124 (21)

[43] Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product) [J].

Walters, Mark C. ;

Rasko, John ;

Hongeng, Suradej ;

Kwiatkowski, Janet ;

Schiller, Gary J. ;

Kletzel, Morris ;

Ho, P. Joy ;

Vichinsky, Elliott ;

von Kalle, Christof ;

Cavazzana, Marina ;

Leboulch, Philippe ;

Petrusich, Alexandria ;

Soni, Sandeep ;

Thompson, Alexis A. .

BLOOD, 2015, 126 (23)

[44] The Guard1 clinical trial - A first in-human, phase 1/2 study evaluating AVR-RD-02, a hematopoietic stem cell (HSC) gene therapy for Gaucher disease: Preliminary safety, pharmacodynamic and clinical efficacy results from the subjects observed for up to 24 months post-infusion [J].

Adera, Mathews ;

Veselinovic, Milena ;

Treohan, Anita ;

Golipour, Azadeh ;

Ridha, Essra .

MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) :3-4

← 1 2 3 4 5 →